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Protein transduction domain mimic (PTDM)The mechanism(s) by which certain small peptides and peptide mimics carry large cargoes across membranes
through exclusively non-covalent interactions has been difﬁcult to resolve. Here, we use the droplet-interface
bilayer as a platform to characterize distinct mechanistic differences between two such carriers: Pep-1 and a
guanidinium-rich peptide mimic we call D9. While both Pep-1 and D9 can carry an enzyme, horseradish perox-
idase (HRP) across a lipid bilayer, we found that they do so by different mechanisms. Speciﬁcally, Pep-1 requires
voltage or membrane asymmetry while D9 does not. In addition, D9 can facilitate HRP transport without pre-
forming a complex with HRP. By contrast, complex formation is required by Pep-1. Both carriers are capable of
forming pores in membranes but our data hints that these pores are not responsible for cargo transport. Overall,
D9 appears to be a more potent and versatile transporter when compared with Pep-1 because D9 does not re-
quire an applied voltage or other forces to drive transport. Thus, D9 might be used to deliver cargo across mem-
branes under conditions where Pep-1 would be ineffective.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Cell-penetrating peptides (CPPs) and protein transduction domains
(PTDs) facilitate the translocation of large molecules into cells [1].
Most are covalently linked to their cargo and enter cells through endo-
cytosis [2–3]. However, a small subset possesses two remarkable traits.
Speciﬁcally, peptides such as Pep-1 [4–6] and polyarginine (polyR)
[7–12] do not need to be covalently tethered to cargoes. In addition,
these carriers appear to deliver their cargoes directly to the cytoplasm,
bypassing endocytosis. The mechanism(s) by which non-covalent,
non-endocytotic carriers deliver cargoes has proven difﬁcult to resolve
and remains an active area of research.
As an example, consider the differences observed in the transloca-
tion action of Pep-1 and guanidinium-rich domains such as
polyarginine. Pep-1 is believed to work by ﬁrst forming a complex
with its cargo through electrostatic and/or hydrophobic interactions
[5,13]. A ratio of 20:1 Pep-1:cargo is typical of a translocation scheme.
Studies at 4 °C, where energy-dependent endocytosis is inactivated,
show that Pep-1 can carry a cargo into the cytoplasm [14]. However,
at 37 °C endocytosis is the predominant transport mode [14]. Experi-
ments using artiﬁcial membranes (vesicles) at room temperature
showed that Pep-1-mediated protein transport across lipid bilayers re-
quired negatively-charged lipids and a transmembrane voltage gradient
[6]. Some have suggested that Pep-1 forms pores inmembranes that fa-
cilitate the trafﬁcking of molecular cargo [15–18]. This is supported bythe fact that Pep-1 induces pore-like defects in bilayers that are clearly
visible in ionic current measurements [18]. Models of Pep-1's mecha-
nism, based on pore formation, have been proposed but others have
countered this idea suggesting that Pep-1 simply disintegrates the
membrane [19–20].
Pep-1 consists of three domains: a tryptophan-rich hydrophobic re-
gion, a ﬂexible linker and a lysine-rich domain. In addition, the ends of
the peptide are capped by acetyl and cysteamide groups, meaning that
in neutral buffer Pep-1 exists as a disulﬁde-linked dimer [5]. This struc-
ture contrasts sharply with guanidinium-rich carriers such as polyRs,
where the structure is uniform from end to end. As with Pep-1, polyR
cargo is transported directly to the cytoplasm in some cases and there
is also some evidence that shows that endocytosis is dominant unless
translocation is performed at low temperature [14]. Others argue that
molecular transport is dependent on both energy and the presence of
certain lipid domains in the membrane [21]. The notion of pore forma-
tion induced by guanidinium-rich species is also contentious. PolyR and
syntheticmimics do inducemembrane curvature inmodel bilayers [22].
However, ﬂuorescent dye molecules outside cells do not enter the cyto-
plasm when the cell is exposed to arginine-rich TAT peptides, some-
thing that would be expected if TAT formed pores [23]. By contrast,
experiments showed that lowmolecular weight (3 kDa) dextran mole-
cules within giant unilamellar vesicles (GUVs) were released when the
membrane was exposed to TAT [24]. Larger molecular weights
remained trapped, leading to the expectation that pores were between
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that guanidinium-rich carriers form pores in lipid bilayers [12,25].
It is important to note that guanidinium-rich carriers have been
studied in two distinct modes. In the ﬁrst, carriers and cargo are
mixed to induce cargo delivery across a membrane [9,21,26–27]. In a
recent example, a protein transduction domain mimic (PTDM) in the
form of a guanidinium functionalized polymer was used to deliver
siRNA into T cells [26]. In the second, carrier and cargo are on opposite
sides of the bilayer, such as carrier-mediated release of contents from
vesicles [9,24]. One intriguing idea that has emerged from this mode is
the importance of anions in transport. Previous reports show that hy-
drophobic anions (termed activators) facilitate the movement of
polyarginine across lipid bilayers [27]. Importantly, the guanidinium
groups havehigh anion afﬁnity (contrast to the low afﬁnity of lysine res-
idues in Pep-1) and thus may permeate the membrane upon charge
neutralization. Here, pore formation is not a prerequisite for transloca-
tion, nor is there any need to preform a complex since cargo and carrier
are on opposite sides of themembrane. From this, a very interesting sce-
nario emerges. Guanidinium-rich carriers enter the membrane bound
to one ion and upon reaching the other side, exchange anionic cargo.
The new complex crosses back to extract the cargo. The idea that
guanidinium-rich speciesmight “reach across”membranes towithdraw
anions (termed interface-directed translocation) has been demonstrat-
ed with small cargoes [9].
Here, we conducted a series of translocation studies using either a
lysine-rich carrier (Pep-1) or a guanidinium-rich carrier (D9) and com-
pared the results. We found that, unlike Pep-1, guanidinium-based
carriers trafﬁcked molecular cargo without the need for an applied
voltage or asymmetric membrane. Moreover, the D9 carrier was able
to “extract” protein cargo from the opposite side of a membrane, there-
by highlighting a unique capability of the carrier.
2. Methods and materials
2.1. Materials
Pep-1 (Ac-KETWWETWWWEWSQPKKKRKV-Cya)was obtained from
Active Motif (Carlsbad, CA). Horseradish peroxidase (HRP, peroxidase
type XII from horseradish) and hexadecane were obtained from Sigma-
Aldrich. Maleic anhydride, furan, 4-dimethylaminopyridine (DMAP), 1-
(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC),
1,3-di-boc-2-(2-hydroxyethyl)guanidine, N-hydroxysuccinimide,
norbornene acid, 4-chloro-7-nitrobenzofurazan, N-boc-ethylenediamine,
N,N-diisopropylethylamine (DIPEA), ethyl vinyl ether, triﬂuoroacetic acid
(TFA), methanol (MeOH), ethyl acetate (EtOAc), pentane, N,N-
dimethylformamide (DMF), hexanes and tetrahydrofuran (THF) were
obtained as reagent grade from Aldrich, Fisher Scientiﬁc, Fluka or Acros
and used as received. 3rd generation Grubbs catalyst (dichloro-di(3-
bromopyridino)-N,N′-dimesitylenoimidazolino-Ru = CHPh; G3) was
synthesized as described previously by Grubbs and coworkers. 1Fig. 1. Carrier-mediated transport across a droplet-interface bilayer (DIB). (a) Carriers transport
within each droplet are used to record the ionic current and membrane capacitance. Following
(b) An NBD-labeled diguanidine polymer (9-mer) or Pep-1 was used to facilitate transport.Dichloromethane (CH2Cl2) (HPLC grade, Fisher Scientiﬁc) was distilled
from CaH2 under nitrogen. Spectra/Por® Biotech Cellulose Ester (CE)
dialysis membranes with a molecular weight cutoff (MWCO) of
100–500 g/mol were purchased from Spectrum Medical Industries. The
Amplex Red enzymatic substrate for HRP was obtained from Invitrogen.
Low melting point agarose, hydrogen peroxide and HEPES buffer
were obtained from Fisher Scientiﬁc. 1,2-Diphytanoyl-sn-glycero-3-
phosphocholine (DPhPC), 1,2-diphytanoyl-sn-glycero-3-phospho-(1′-
rac-glycerol) (sodium salt) (DPhPG), and egg yolk phosphatidylcholine
(EYPC) lipids were purchased from Avanti Polar Lipids (Alabaster, AL)
and 5(6)-carboxyﬂuorescein (CF) was purchased from Fluka.
2.2. Preparation of DPhPC and DPhPC/DPhPG vesicles
All vesicle solutions were prepared in 10 mM HEPES and 150 mM
NaCl was buffered to pH 7.4 with sodium hydroxide. 2 mMDPhPC ves-
icle solution was prepared by air-drying an aliquot of DPhPC in pentane
until the solvent was removed, followed by further drying in a vacuum
desiccator for 30 min. Lipids were resuspended in buffer and extruded
21 times through a polycarbonate ﬁlter with 100 nm track-etched
pores (Millipore) using a mini-extruder (Avanti). For negatively
charged vesicles, a 2 mM solution was prepared with a 9:1 M ratio of
DPhPC to DPhPG.
2.3. Preparation of Pep-1 complexes and D9-NBD/HRP mixtures
A 500 μM stock solution of Pep-1 was prepared by dissolution in
18 MΩwater and was then stored as 5 μL aliquots in lo-bind eppendorf
tubes at−20 °C. A 50 μM stock solution of HRP was prepared by disso-
lution in 18 MΩ water and was then stored as aliquots at −20 °C.
50 mM Amplex Red was prepared by dissolution in DMSO and stored
at−4 °C. Pep-1/HRP complexes were prepared fresh from the stock so-
lutions prior to each experiment. First, Pep-1 and HRP were diluted in
water to 40 μM and 2 μM, respectively. Second, equal volumes of these
dilutions were mixed and incubated at room temperature for 30 min.
Finally, a 2 μL aliquot of complex was mixed with 18 μL of vesicle solu-
tion to create the solution used as the source droplet. The ﬁnal concen-
trations of Pep-1 and HRP in the complex containing droplet were 2 μM
and 100 nM, respectively.
2.4. Preparation of D9-NBD/HRP complexes
A 2 mM stock solution of D9-NBD was stored in DMSO as 50 μL ali-
quots. A 50 μM stock solution of HRP was prepared by dissolution in
18MΩwater and stored in aliquots at−20 °C. D9-NBD/HRP complexes
were prepared fresh from the stock solutions prior to each experiment.
First, D9-NBD and HRP were diluted in water. Second, equal volumes of
these dilutions were mixed and incubated at room temperature for
30min. In experimentswhere theD9-NBD andHRPwere present in op-
posing droplets, the D9-NBD and HRPwere incubated separately with aan enzyme (HRP) from the source to the capture droplet during a ﬁxed interval. Electrodes
translocation the capture droplet is analyzed for enzyme activity via a ﬂuorescence assay.
Fig. 3. D9-NBD facilitated transport as a function of voltage. Regardless of the presence or
polarity of applied potential, little variation in the quantity of translocated HRP was
observed.
Fig. 2. Concentration dependence of D9-NBD on HRP translocation across PC DIBs. The left
data set (i) demonstrates D9-NBD's activity as a protein carrier. Controls show reduced
transport at (ii) lower concentration and (iii) absence of carrier. Finally, droplets were
contacted, then detached before DIB formation (iv). This demonstrated that merely
contacting droplets does not transfer HRP. The third data set from the left was previously
published [31] and is included here for comparison.
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iquot of complex was mixed with 18 μL of vesicle solution to create the
solution used as the source droplet. The ﬁnal concentrations of D9-NBD
and HRP in the source droplet were in a 20:1 ratio in all trials.
2.5. Electrophysiology
The electrodes were connected to a patch-clamp ampliﬁer
(Axopatch 200B; Axon Instruments). The currents were ﬁltered with a
low-pass Bessel ﬁlter (80 dB/decade) with a corner frequency of 2 kHz
and then digitized with a DigiData 1400 series A/D converter (Axon
Instruments) at a sampling frequency of 5 kHz. The oil reservoir and
amplifying headstage were enclosed in a metal box, which served as a
Faraday cage.
We examined the membrane activity of D9-NBD both in the
presence and absence of HRP (Figure S7). Regardless of the polarity of
the applied potential or the presence of HRP, transient pores formed
in the DIB membrane. Typically, more “pore-forming activity” is ob-
served in the ﬁrst half of the trace when compared with the second
half. By 10 min, the conductance of the membrane approaches zero pA.
3. Results and discussion
Here, we employ droplet-interface bilayers (DIBs) as model mem-
branes to investigate the nuances of carrier-mediated translocation.
Brieﬂy, monolayer-encased aqueous droplets are contacted under oil
to form a lipid bilayer [28–29]. Electrodes embedded within the drop-
lets permit monitoring of the bilayer by ionic current recording during
translocation. In these experiments, the enzymehorseradish peroxidase
(HRP) is used as the cargo. HRP (44 kDa) translocation from the source
droplet to the capture droplet is facilitated both by carrier molecules
and experimental conditions such as lipid composition, symmetry or
applied voltage (Fig. 1a). In all DIB experiments, membranes were
composed of DPhPC with or without a mole fraction of DPhPG lipids.
By manipulating the PC:PG headgroup ratio of each leaﬂet, asymmetric
membranes were created. Diphytanoyl lipid tails were used in these
experiments since they do not undergo phase transitions near the tem-
peratures used in our experiments [30]. Captured enzymes were subse-
quently analyzed by a ﬂuorogenic assay. We have previously used this
approach to examine HRP transport mediated by the cell-penetrating
peptide Pep-1 [31]. Now we turn our attention to a guanidinium-rich,
polyarginine inspired polymer as a model carrier in an effort to under-
stand the relationship between carrier chemistry and translocation
mechanism. D9-NBD is a monodisperse, guanidinium-rich 9-mer syn-
thesized by ring-opening metathesis polymerization [26,32–34]. This
method is ideal because it is fast, efﬁcient (high monomer conversion),
and yields polymers with well-controlled molecular weights and
dispersities. The detailed synthetic procedures are provided in the
Supporting information. At one end, a nitrobenzoxadiazole (NBD)
ﬂuorophore is attached for visualization. D9-NBD was originally de-
signed to mimic the prototypical CPP, TAT. This PTDM, with two guani-
dines per repeat unit, was shown to be more effective at cellular
internalization than its corresponding one-guanidine counterpart [33].
To test D9-NBD's translocation ability, 8 μM D9-NBD and 400 nM HRP
were incubated together for 30 min and then diluted 10-fold with a so-
lution containing 2 mM lipid vesicles. Next, 200 nL of this mixture was
suspended from the electrically grounded electrode to form the source
droplet. A droplet of vesicleswas suspended from theworking electrode
to create the capture droplet and the two were contacted to form a DIB.
In this trial, the DIB was composed of pure phosphatidylcholine (PC)
lipids and the ﬁnal concentrations in the source droplet were 800 nM
D9-NBD and 40 nM HRP. Following a 10 min translocation period at
an applied potential of−50 mV, an average of 0.4 pM of HRP was de-
tected in the capture droplet by ﬂuorogenic assay (Fig. 2) [31]. This
amount is similar to our previous studies, where Pep-1 (2 μM) carried
HRP (100 nM) across the DIB during a 45 minute interval to yield anaverage of 1.1 pM translocated enzyme [31]. Note that theD9-NBD trials
occurred for a shorter interval and lower concentration of carrier and
cargo, thus we surmise that D9-NBD is a more potent carrier than
Pep-1. We used 800 nM D9-NBD for these experiments because higher
concentrations easily ruptured the DIB membrane. We also examined
the concentration dependence of D9-NBDHRP transport. A four-fold di-
lution of the D9-NBDHRPmixture or absence of carrier greatly reduced
translocation. As a control, the 800 nMD9-NBD 40 nMHRP trial was re-
peated but with one important change. The droplets were contacted
only brieﬂy and then separated (no DIB formed) and the source droplet
was analyzed for enzyme activity. In 10 trials, no enzyme activity was
detected, showing that translocation occurs only across the DIB mem-
brane and not by other means. Pep-1-mediated transport is facilitated
by the application of a transmembrane potential or lipid charge
asymmetry [31]. We were curious to see if D9-NBD translocation also
required similar conditions. In contrast to Pep-1, we found that approx-
imately the same amount of HRP is carried across the DIB by D9-NBD
regardless of the applied potential polarity (Fig. 3). In addition, while
Pep-1 could not transport HRP across a pure PC DIB at 0 mV applied po-
tential, D9-NBD spontaneously carried HRP across a neutrally charged
membranewith no voltage (Fig. 3). Sincemembrane charge asymmetry
can drive Pep-1 mediated translocation in the absence of voltage [31],
we also examined the effect of lipid asymmetry on D9-NBD mediated
Fig. 4.D9-NBD facilitated transport as a function of membrane charge symmetry. 10mol%
of a PG lipid was added to either or both sides of DIBs to create negatively-charged leaﬂet;
the remaining lipidswere neutral PC. Similar amounts of HRPwere transported regardless
of charge asymmetry.
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that contained 10 mol% of negatively-charged phosphatidylglycerol
(PG) and 90% PC lipids in one or both leaﬂets. Unlike Pep-1, D9-NBD
based translocation of HRP showed no signiﬁcant dependence on
charge distribution in the DIBs (Fig. 4). The addition of a voltage bias
did not increase translocation across an asymmetric DIB (Fig. 4). The
lack of dependence of D9-NBD facilitated HRP transport on either volt-
age or membrane asymmetry suggests that D9 and perhaps other
guanidinium-rich carriers may function by a different mechanism
than Pep-1.
To explore these differences further, we examined the relationship
between complex formation and carrier-mediated transport using D9-
NBD and Pep-1. In these experiments, the cargo and carrier were placedFig. 5. Transport as a function of complex formation. Either Pep-1 or D9-NBDwas used to trans
0 mV. Remarkably, D9-NBD facilitates signiﬁcantly more translocation when arranged opposite
lished previously[30] and the third data set is copied from Fig. 1 for comparison. Inset: 50mMceither in the same droplet or in opposite droplets. For Pep-1, HRP trans-
port was not observed in either case. However, D9-NBD showed a re-
markable increase in HRP transport when placed on the opposite side
of the DIB from HRP (Fig. 5). Further, DLS measurements indicate that
D9-NBD does not adsorb to HRP when they are incubated together
(Table S2). Two important ideas emerge from these results. First, inter-
actions between D9 and HRP, such as an incubation period, are not a
prerequisite for translocation. This contrasts with Pep-1 where several
literature reports emphasize the importance of both incubation and
the peptide to cargo molar ratio. Second, transport is enhanced when
the cargo and carrier are separated. Guanidinium-rich peptides have al-
ready been shown to “reach across” vesiclemembranes to extract bulky
anions [9]. D9-NBD is also capable of extracting bulky anions, in this case
carboxyﬂuorescein, fromvesicles in a concentration-dependentmanner
(Fig. 5, inset). Our data suggests that this idea might be extended to
larger entities such as entire proteins. Following several of the DIB ex-
periments presented here, we imaged the capture droplet by ﬂuores-
cence microscopy to measure how much D9-NBD crossed over after
translocation.
However, very little D9-NBD was detected in the capture droplets
(except where D9-NBD and HRP were in separate droplets) (Fig. S8).
This does not necessarily indicate that D9 cannot cross the DIB, but at
least it does not rapidly equilibrate across the membrane. Models like
carpet, toroidal pore and barrel stave are insufﬁcient to explain the
transport of molecular cargo observed in our experiments with Pep-1
and D9 as carriers [16,35–36]. We note that both Pep-1 [31] and D9
form pores in DIB membranes in the absence and presence of cargo
(Fig. S7). This suggests that the requirement for complex formation
(as with Pep-1) [5] may not be related to the formation of pores in the
membrane. If so, perhaps translocation does not take place by passing
through carrier-lined pores but instead by someothermeans. For exam-
ple, the hydrophobic regions of either D9 or Pep-1 could interact with
the hydrophobic core of the membrane while the positive regions neu-
tralize negatively-charged patches on the cargo. The lysine-rich Pep-1port HRP either from the same or the opposite side of the DIB. All trials were conducted at
to the source droplet. No transport is observed with Pep-1. The second data set was pub-
arboxyﬂuorescein was extracted from lipid vesicles as a function of D9-NBD concentration.
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guanidinium-rich D9, which might explain the need for voltage or
lipid charge asymmetry when using Pep-1. So far, the DIB experiments
have revealed that these two pore-forming carriers work very different-
ly under well-deﬁned conditions and that further investigation is need-
ed to understand these differences.
Here, we have shown that the guanidinium-rich D9-NBD polymer
can facilitate transport of a protein cargo across a lipid bilayer without
the requirement of negative charge or voltage. In addition, its ability
to transport this protein is enhanced when the carrier-cargo is not
pre-mixed demonstrating that pre-formed complexes are not required
for transport. The DIB system is ideally suited for probing themechanis-
tic details of various carriers and enables well-deﬁned, independent
variables to be studied in isolation which are more difﬁcult to accom-
plish in many bulk studies. Given the complex landscape of CPP related
transport, or internalization, we are motivated to continue studying
these systems as broadly as possible. The growing use of CPPs and relat-
ed molecules in molecular delivery applications highlights the need for
more fundamental studies of the delivery mechanism. Learning how to
develop more effective carriers is vital to researchers in many different
ﬁelds.
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